Pfizer Inc. Release: Breast Cancer Guidelines Confirm Central Role of ‘Switch Strategy'; Recommendations of St Gallen Panel Support Exemestane Indication

PARIS--(BUSINESS WIRE)--Guidelines from the 2007 St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer, published today in the Annals of Oncology (http://annonc.oxfordjournals.org), confirm the value of switching from tamoxifen to an aromatase inhibitor (AI), such as exemestane, for the adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer.i

MORE ON THIS TOPIC